Loading organizations...

§ Private Profile · Singapore, Singapore
Nalagenetics is a technology company.
Nalagenetics delivers genetic testing solutions providing personalized health insights, uniquely tailored for Southeast Asia's diverse genetic profiles. Its core product utilizes genomic analysis to inform decisions on nutrition, cancer risk, and lifestyle. By predicting individual medication responses, the company aims to reduce adverse drug reactions and enhance the overall efficacy of pharmaceutical treatments.
Co-founded in April 2016 by Levana Sani, Astrid Irwanto, Jianjun Liu, and Alexander Lezhava, Nalagenetics originated from their collective work at the Genome Institute of Singapore. They identified a significant need for accessible, region-specific genetic data. This insight fueled their mission to translate complex genomic science into practical, individualized health interventions.
Nalagenetics serves individuals seeking to understand health predispositions and optimize well-being via genetic insights. Its services offer tailored reports on nutrient metabolism and pharmacogenomics, empowering users with actionable health intelligence. The company envisions democratizing preventive, DNA-based precision healthcare for more effective and safer health management strategies.
Nalagenetics has raised $13.0M across 1 funding round.
Nalagenetics has raised $13.0M in total across 1 funding round.
Nalagenetics has raised $13.0M in total across 1 funding round.
Nalagenetics's investors include Intudo Ventures, Vulcan Capital, A*ccelerate Technologies, Dexa International, Diagnos Laboratories.
Nalagenetics (also stylized NalaGenetics or NALA) is a Singapore-headquartered biotechnology company that builds pharmacogenomics and population-tailored genetic testing products and clinical decision–support tools to make medication and preventive-health decisions more precise for Southeast Asian populations[5][1].
High-Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Nalagenetics is a regionally focused PGx and precision‑health company that converts field‑driven clinical insights into interoperable test kits and decision‑support software, positioning itself to be a practical bridge between genomic science and clinical practice in Southeast Asia[4][5][1].
Nalagenetics has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Series A in March 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2022 | $13M Series A | Intudo Ventures, Vulcan Capital | A*ccelerate Technologies, Dexa International, Diagnos Laboratories | Announced |